A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma

Cancer Treat Rev. 2019 Jan:72:37-44. doi: 10.1016/j.ctrv.2018.11.003. Epub 2018 Nov 15.

Abstract

Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10-20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MLS.

Keywords: MLS; Myxoid liposarcomas; Trabectedin.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Humans
  • Liposarcoma, Myxoid / drug therapy*
  • Trabectedin / therapeutic use*

Substances

  • Antineoplastic Agents, Alkylating
  • Trabectedin